Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Metabolomic profiling of mouse heart in a model of Cardiovascular-Kidney-Metabolic syndrome

ABSTRACT:

Cardiovascular-kidney-metabolic (CKM) syndrome is a complex systemic disorder. In this study, we developed a urea-activated nanoparticle (T-PAAD NP) for targeted delivery of Empagliflozin to the renal S1 segment. Untargeted GC-MS-based metabolomics was performed to characterize metabolic reprogramming in heart tissues of a CKM mouse model.

INSTRUMENT(S): Gas Chromatography MS - positive

PROVIDER: MTBLS13991 | MetaboLights | 2026-03-21

REPOSITORIES: MetaboLights

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	a_MTBLS13991_GC-MS_positive__metabolite_profiling.txt	Txt
	i_Investigation.txt	Txt
	m_MTBLS13991_GC-MS_positive__metabolite_profiling_v2_maf.tsv	Tabular
	s_MTBLS13991.txt	Txt

Items per page:

1 - 4 of 4

Similar Datasets

Metabolomic profiling of mouse kidney in a model of Cardiovascular-Kidney-Metabolic syndrome

Project description:<p>Cardiovascular-kidney-metabolic (CKM) syndrome is a complex systemic disorder. In this study, we developed a urea-activated nanoparticle (T-PAAD NP) for targeted delivery of Empagliflozin to the renal S1 segment. Untargeted GC-MS-based metabolomics was performed to characterize metabolic reprogramming in kidney tissues of a CKM mouse model.</p>

2026-03-21 | MTBLS13988 | MetaboLights

Restoration of branched chain amino acid catabolism improves kidney function in preclinical cardiovascular-kidney-metabolic syndrome models

Project description:Patients with metabolic syndrome and heart failure (HF) often have accompanying kidney dysfunction, which was recently defined as cardiovascular-kidney-metabolic (CKM) syndrome. Prior metabolomics profiling of metabolic syndrome patients identified a plasma branched chain amino acid (BCAA) signature, and BCAAs are elevated in HF patient myocardium. The rate limiting step of BCAA catabolism is decarboxylation by branched chain ketoacid dehydrogenase enzyme (BCKDH), which is negatively regulated by BCKDH kinase (BCKDK or BDK), and BDK inhibitors improve metabolism and heart failure preclinically. Here we show that BCAA catabolic impairment is associated with and may be causal to CKM as treatment with the BDK inhibitor BT2 improved urine protein content, glomerular filtration rate, kidney hypertrophy, and kidney pathology in CKM models. Coadministration of BT2 and empagliflozin restored renal function and gene expression signatures and improved mitochondrial density and function, suggesting that BDK inhibition could represent a therapeutic avenue for CKM.

2025-06-01 | GSE263155 | GEO

Finerenone added to RAS/SGLT2 blockade for non-diabetic chronic kidney disease. Results of a preclinical double-blinded randomized controlled trial.

Project description:The goal of this study was to compare Next Generation mRNA (RNA-seq) data obtained from whole kidney tissue from WT and untreated, Ramipril treated, and Ramipril/Empagliflozin treated, and Ramipril/Empagliflozin/Finerenone treated Col4a3-/- mice in the 129/SvJ background.

2023-09-01 | GSE226353 | GEO

Glutaminase 2 Knockdown Reduces Hyperammonemia and Associated Lethality of Urea Cycle Disorder Mouse Model

Project description:Urea cycle disorders with hyperammonemia remain difficult to treat and eventually necessitate liver transplantation. An ornithine transcarbamylase defect (Otcspf-ash) mouse model, a model of urea cycle disorder, was used to test whether knockdown of a key glutamine metabolism enzyme glutaminase 2 (Gls2) or glutamine dehydrogenase 1 (Glud1) could rescue the hyperammonemia and associated lethality induced by a high protein diet. Reduced hepatic expression of Gls2, but not Glud1, by AAV8-mediated delivery of a short hairpin RNA in Otcspf-ash mice diminished hyperammonemia, reduced body weight loss, and reduced lethality. These data suggest that Gls2 hepatic knockdown could help alleviate risk for hyperammonemia and other clinical manifestations of patients suffering from defects in the urea cycle.

2022-06-07 | GSE179342 | GEO

Apatite nanoparticle(sCA)-siTIMP1 delivery in NIH3T3

Project description:Apatite nanoparticle(sCA)-siTIMP1 delivery in NIH3T3

| PRJNA526507 | ENA

Therapeutic Delivery of Targeted Nanoparticle Cannabinoid Equivalents

Project description:Therapeutic Delivery of Targeted Nanoparticle Cannabinoid Equivalents

| PRJNA849515 | ENA

Bone marrow naïve B lymphocytes improve heart function after myocardial infarction [RNA-Seq]

Project description:We provided an mRNA-seq analyses of mouse bone marrow revealing B cell development arrest in the bone marrow after MI, which was restored by treatment of empagliflozin (EMPA).

2022-10-10 | GSE193425 | GEO

Prevention of mammary tumor progression by silencing HoxA1 via intraductal injection of nanoparticle-formulated siRNA

Project description:Silencing HoxA1 in vivo by intraductal delivery of nanoparticle-formulated siRNA reduced mammary tumor incidence by 75% , reduced cell proliferation, and prevented loss of ER and PR expression. 8 week wild type FVB mouse whole mammary gland and 8week to 20 week transgenic FVB C3(1)-SV40Tag mouse whole mammary gland

2013-12-31 | E-GEOD-50813 | biostudies-arrayexpress

Bone marrow naïve B lymphocytes improve heart function after myocardial infarction [scRNA-Seq]

Project description:We provided a single cell mRNA-seq analyses of mouse bone marrow revealing B cell development arrest in the bone marrow after MI, which was restored by treatment of empagliflozin (EMPA).

2022-10-10 | GSE193316 | GEO

Proteomic Analysis insights into Potential Mechanism of SGLT2 Inhibitors cardiovascular benefit in Diabetic cardiomyopathy

Project description:Diabetic cardiomyopathy (DCM) is one of the major causes of heart failure in diabetic patients, but its pathogenesis remains unclear. Sodium glucose cotransporter 2 inhibitors (SGLT2i) can effectively reduce the risk of cardiovascular death and heart failure in DCM patients, but the underlying mechanism has not been elucidated. We established a DCM rat model followed by treatment with empagliflozin (EMPA) for 12 weeks. The proteomics of the myocardium in the rat model was performed to identify the potential targets and signaling pathways associated with the cardiovascular benefit of SGLT2i.

2023-03-10 | PXD036090 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data